Impax Laboratories Earnings: Everything You Must Know Now

Impax Laboratories Inc. (NASDAQ:IPXL) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Impax Laboratories Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 28.85% to $0.37 in the quarter versus EPS of $0.52 in the year-earlier quarter.

Revenue: Rose 15.5% to $148.5 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Impax Laboratories Inc. reported adjusted EPS income of $0.37 per share. By that measure, the company beat the mean analyst estimate of $0.21. It beat the average revenue estimate of $128.85 million.

Quoting Management: In the first quarter 2013, the Company recorded an inventory reserve of $6.7 million as stated above. This charge was the result of a strategic review conducted by the Company with a third party consulting firm of the Company’s currently manufactured generic product portfolio. This review was completed during the first quarter 2013 and the Company decided to discontinue manufacturing a number of low-sales/low-margin mature products. The total net sales of these products in 2012 were less than 3% of the total Company product revenues, with minimal impact on net income. The Company is currently reviewing manufacturing costs and expects that the discontinuation of these products and other efficiencies will result in cost savings of approximately $10.0 million for the full year 2013, which has been reflected in the revised full year gross margin guidance.

“We expect that this decision will improve operating efficiencies and ensures that resources are allocated and aligned with our strategic growth priorities,” said Larry Hsu, Ph.D., president and CEO, Impax Laboratories, Inc. “We will continue to look for opportunities to free up resources that can be invested to best position Impax for a strong future.”

Key Stats (on next page)…

Revenue increased 5.26% from $141.08 million in the previous quarter. EPS increased 23.33% from $0.30 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.16 to a profit $0.12. For the current year, the average estimate has moved down from a profit of $0.75 to a profit of $0.48 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]